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AbstrACt
Introduction Patients with muscle invasive bladder 
cancer (MIBC) who are unfit and unsuitable for standard 
radical treatment with cystectomy or daily radiotherapy 
present a large unmet clinical need. Untreated, they 
suffer high cancer specific mortality and risk significant 
disease- related local symptoms. Hypofractionated 
radiotherapy (delivering higher doses in fewer fractions/
visits) is a potential treatment solution but could be 
compromised by the mobile nature of the bladder, 
resulting in target misses in a significant proportion 
of fractions. Adaptive ‘plan of the day’ image- guided 
radiotherapy delivery may improve the precision and 
accuracy of treatment. We aim to demonstrate within a 
randomised multicentre phase II trial feasibility of plan of 
the day hypofractionated bladder radiotherapy delivery 
with acceptable rates of toxicity.
Methods and analysis Patients with T2- T4aN0M0 MIBC 
receiving 36 Gy in 6- weekly fractions are randomised (1:1) 
between treatment delivered using a single- standard plan 
or adaptive radiotherapy using a library of three plans 
(small, medium and large). A cone beam CT taken prior 
to each treatment is used to visualise the anatomy and 
select the most appropriate plan depending on the bladder 
shape and size. A comprehensive radiotherapy quality 
assurance programme has been instituted to ensure 
standardisation of radiotherapy planning and delivery. 
The primary endpoint is to exclude >30% acute grade 
>3 non- genitourinary toxicity at 3 months for adaptive 
radiotherapy in patients who received >1 fraction (p0=0.7, 
p1=0.9, α=0.05, β=0.2). Secondary endpoints include 
local disease control, symptom control, late toxicity, 
overall survival, patient- reported outcomes and proportion 
of fractions benefiting from adaptive planning. Target 
recruitment is 62 patients.
Ethics and dissemination The trial is approved by the 
London- Surrey Borders Research Ethics Committee (13/
LO/1350). The results will be disseminated via peer- 
reviewed scientific journals, conference presentations and 
submission to regulatory authorities.
trial registration number NCT01810757.
IntroduCtIon
Standard radical management of muscle inva-
sive bladder cancer (MIBC) involves either 
radical cystectomy or a course of daily radio-
therapy delivered with radiosensitisation over 
4–7 weeks.1–5 Given the aetiological associa-
tion of bladder cancer with smoking, cardio-
vascular and respiratory comorbidities are 
common.6 7 Undertreatment and poor access 
to effective treatment are particularly evident 
in older patient groups who have the highest 
risk of cancer related morbidity and death 
from initially curable bladder cancer.8
Hypofractionated radiotherapy (deliv-
ering higher doses in fewer fractions/visits) 
may provide a potential treatment solution 
for these patients. The only multicentre 
randomised control trial of hypofractionated 
bladder radiotherapy investigated two sched-
ules of relatively low biological effectiveness; 
strengths and limitations of this study
 ► This is a phase II national multicentre randomised 
control trial evaluating innovation in radiotherapy 
technology (strength).
 ► The trial has a non- comparative single- stage design 
(limitation).
 ► Detailed guidance and training for this novel ra-
diotherapy technique are provided to ensure stan-
dardisation across multiple participating centres 
(strength).
 ► A robust pretrial and on trial radiotherapy quality as-
surance programme is in place to ensure standardi-
sation of a trial technique (strength).
 ► Primary endpoint focus is based on determining 
early effectiveness of this approach as measured by 
acute non- genitourinary grade three toxicity scoring 
(strength).
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35 Gy in 10 fractions over 2 weeks and 21 Gy in 3 fractions 
over 1 week.9 Both treatment groups achieved similar 
symptom control with no significant difference in effi-
cacy or toxicity evident between different radiotherapy 
schedules. Despite the palliative treatment intent, 
approximately 20% of patients achieved survival beyond 
24 months.9 Given the presumed dose–response relation-
ship of MIBC to radiotherapy, a higher biological effec-
tive dose would be expected to improve local disease and 
symptom control further.10
A number of small single- centre studies using the 
higher biological dose of 30–36 Gy in 6 Gy per fraction 
suggest acceptable acute and late toxicity with local 
control achieved in over of 60% patients at 3 months.11–13 
Prospective multicentre assessment of this radiotherapy 
schedule has not yet been performed.
Reliably targeting the bladder for radiotherapy is 
challenging. It is a relatively mobile structure subject 
to marked shape and volume change during a course 
of radiotherapy.14–16 This has meant that historically 
bladder cancer radiotherapy has been delivered with 
some element of geographical miss (up to 57% of frac-
tions) even when large safety margins of upto 1.5 cm are 
applied to create the planning target volume (PTV).17 
The expected consequence of dose intended for the 
target hitting adjacent normal structures is reduced 
tumor control and increased treatment related toxicity. 
Larger safety margins would more reliably encompass the 
bladder target variation but would further increase the 
normal tissue exposed to radiation dose, so increase side 
effects from treatment.
Volumetric soft- tissue imaging made possible by cone 
beam CT (CBCT) technology integrated on current 
generation linear accelerators allows a three- dimensional 
image to be acquired immediately prior to treatment. This 
informs positional adjustment to optimise target coverage 
by the radiotherapy plan. It also has enabled ‘plan of the 
day’ solution. Rather than a single plan available for treat-
ment, a library of plans can be created to cover the range 
of expected filling and positional variation of the bladder. 
Acquiring CBCT just prior to treatment allows visualisa-
tion of the soft tissue so that a plan which best covers the 
bladder target with least normal tissue irradiation can be 
selected for treatment that day.17
In a single- centre non- randomised phase II study, we 
demonstrated feasibility of the plan of the day approach 
using library of three plans in a patient population with 
MIBC unfit for radical treatment.18 Target coverage was 
maintained with reduction in dose to normal tissue irradia-
tion compared with single standard plan.19 The multicentre 
randomised phase II study of HYpofractionated Bladder 
Radiotherapy with or without Image guided aDaptive plan-
ning (HYBRID) seeks to examine whether this treatment 
approach can be consistently and safely delivered across 
multiple National Health Service (NHS) centres.
Below, we describe the HYBRID trial protocol with 
particular emphasis on the radiotherapy procedural 
aspects, including preparatory imaging, treatment 
planning, delivery and evaluation, with the aim of 
providing comprehensive description of the radiotherapy 
implemented for the study.
Hypothesis
Adaptive radiotherapy techniques can be delivered at 
multiple centres and result in acceptable levels of acute 
non- genitourinary (GU) side effects experienced by 
patients with MIBC unsuitable for radical daily radio-
therapy or cystectomy.
MAtErIAls And AnAlysIs
study design
HYBRID is a non- blinded multicentre non- comparative 
randomised control phase II trial conducted in accor-
dance with the Research Governance Framework for 
Health and Social Care and principles of Good Clin-
ical Practice. The trial is sponsored by The Institute of 
Cancer Research, registered on the  ClinicalTrials. gov 
database and is included in the National Institute for 
Health Research (NIHR) Clinical Research Network port-
folio. The final ethics approved version of HYBRID trial 
protocol is provided in the online supplementary file 1.
All patients are planned to receive a total dose of 36 
Gy in 6- weekly fractions randomised (1:1) between treat-
ment delivered using a single standard plan (control) or 
adaptive radiotherapy using a library of plans. Randomis-
ation takes place centrally by the trials unit (Clinical Trials 
and Statistics Unit at The Institute of Cancer Research 
(ICR- CTSU)) within a maximum of 6 weeks prior to the 
planned radiotherapy start date.
The primary endpoint is to evaluate acute non- GU 
grade 3 or greater toxicity as assessed using Common 
Terminology Criteria for Adverse Events (CTCAE V.4). 
The secondary endpoints are to assess local disease 
control at 3 months, control rate of presenting symptoms 
as measured by CTCAE V.4, patient- reported outcomes as 
measured by Inflammatory Bowel Disease Questionnaire, 
King’s Health Questionnaire and EQ5D, late toxicity 
as measured by CTCAE V.4 and the Radiation Therapy 
Oncology Group (RTOG) late radiation morbidity 
scoring schema, time to local disease progression, overall 
survival and proportion of fractions benefiting from 
adaptive planning.
The trial has a number of exploratory secondary 
endpoints related to the appropriate identification of 
plan selection, target coverage and concordance between 
clinical and patient- reported outcomes.
Figure 1 shows the trial schema and overview of 
follow- up. Table 1 provides summary of the scheduled 
prerandomisation, on treatment, and post- treatment 
assessments.
Participants and eligibility
Target recruitment is 62 patients from 14 participating UK 
centres. Patients with histological confirmation of inva-
sive bladder cancer (T2- T4aN0M0) of any pathological 
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Figure 1 Trial schema. RTOG, Radiation TherapyOncology Group.
subtype unsuitable for radical cystectomy or radical daily 
radiotherapy for any reason including but not limited to 
performance status, comorbidity or patient refusal will be 
approached for inclusion. Eligible patients would have an 
expected survival of greater than 6 months, be willing to 
accept assessment with cystoscopy following radiotherapy 
completion and be able to attend for follow- up.
Patients with an indwelling urinary catheter, active or 
history of other malignancy within 2 years of randomi-
sation except for non- melanomatous skin carcinoma, 
previous non- muscle invasive bladder tumors and low- risk 
prostate cancer (as defined by National Comprehensive 
Cancer Network (NCCN) risk stratification as T1/T2a, 
Gleason 6 PSA <10) will be excluded. Those with history 
of radiation to the pelvis or other contraindication to 
pelvic radiotherapy, for example, inflammatory bowel 
disease will also be excluded.
study treatment
All participants should have a transuretheral resection of 
the bladder tumor (TURBT) if possible prior to trial entry 
but this is not mandated, accepting that a proportion of 
patients will be unsuitable for this procedure. To permit 
sufficient time for radiotherapy planning, it is expected 
that treatment would commence within a maximum of 6 
weeks from randomisation.
Participants will be planned to receive six, 6 Gy fractions 
delivered weekly to a total dose of 36 Gy. Those allocated 
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Table 2 Clinical target volume (CTV) to planning target volume (PTV) expansion details
Patient randomisation
CTV to PTV expansion (cm)
Laterally Anteriorly Posteriorly Superiorly Inferiorly
Standard plan
  PTV standard 1.5 1.5 1.5 1.5 1.5
Adaptive plan
  PTV small 0.5 0.5 0.5 0.5 0.5
  PTV medium 0.5 1.5 1 1.5 0.5
  PTV large 0.8 2 1.2 2.5 0.8
to the standard planning group will have one radio-
therapy plan generated which will be used to deliver all six 
treatments. A CBCT scan acquired just prior to treatment 
delivery can be used to inform an online position correc-
tion in accordance with National Radiotherapy Imple-
mentation Group (NRIG) Report, on Image Guided 
Radiotherapy (IGRT)20 and standard local practice.
Participants allocated to adaptive planning will have 
three radiotherapy plans generated corresponding to 
a small, medium and large PTV. A CBCT taken imme-
diately prior to each treatment delivery will be used to 
select the most appropriate plan of the day depending on 
the bladder volume and shape. Plan selection is autho-
rised to be carried out only by those radiographers or 
other practitioners (physicians or physicists) who have 
attained concordance with the gold standard PTV selec-
tion through the Radiotherapy Trials Quality Assurance 
(RTTQA) Group IGRT credentialing. This is to ensure all 
those participating in plan selection have the necessary 
advanced skill level required for the study.
radiotherapy planning and delivery
The radiotherapy planning and delivery guidance was 
developed in collaboration with the RTTQA Group.
radiotherapy planning Ct scan
The patient preparation procedures are the same irre-
spective of randomisation arm. Patients are required to 
have an empty bladder for acquisition of the radiotherapy 
planning CT scan. Patients are therefore asked to void 
immediately before planning CT scan and not to drink 
fluids for 30 min before the planning scan. Given bladder 
deformation occurs with loaded rectum, patients are also 
encouraged to evacuate their bowels of flatus and faeces 
prior to scanning. The use of microenemas is permitted if 
it is standard local practice but is not mandated.
Patients are positioned supine with arms comfortably 
positioned out of the radiotherapy field using appro-
priate immobilisation devices. CT slices of <3 mm thick-
ness are obtained from at least 4 cm above the dome of 
the bladder to 2 cm below the ischial tuberosities. No oral 
or intravenous contrast is required.
target volume definition
Volumes are defined according to the International 
Commission on Radiation Units and Measurements 
(ICRU) report 50, supplement report ICRU 62: 
Prescribing, Recording and Reporting Photon Beam 
Therapy and ICRU 83: Prescribing, Recording and 
Reporting Photon- Beam Intensity Modulated radio-
therapy (IMRT).21 Consistent structure naming conven-
tion for target volumes and organs at risk (OAR) is 
adopted for all patients participating within the trial.
Outlining should be carried out with the aid of all 
diagnostic MRI and CT scans wherever available. The 
clinical target volume (CTV) is contoured to encom-
pass the gross tumor volume (GTV), the whole bladder 
and any area of extravesical spread. The CTV includes 
1.5 cm of prostatic urethra in male patients or 1 cm of 
urethra in female patients if tumor is at the base of 
bladder or if distant carcinoma in situ (CIS) is present. 
It is not required that the GTV is drawn as a separate 
structure.
The CTV will be expanded either isotropically by 1.5 cm 
to create a single PTV for standard planning (control) or 
three PTVs using variable margins (small, medium and 
large) for adaptive planning depending on the rando-
misation arm. The CTV to PTV expansion details have 
been derived from earlier phase I/ll work17–19 and are 
summarised in table 2.
organs at risk delineation
OARs are identified as the rectum, other bowel and 
femoral heads. These structures are outlined as solid 
structures by defining their outer wall. The rectum is 
outlined to include the full circumference and rectal 
contents. The rectal outlining should extend from the 
lowest level of the ischial tuberosities to the rectosigmoid 
junction which identified as the level at which there is 
an anterior inflection of the bowel, best appreciated on 
sagittal reconstructions on the CT planning scan.
The small and large bowel (including sigmoid colon) is 
outlined as a single structure labelled other bowel. Small 
and large bowel visible on relevant axial slices of the 
planning scan is outlined as individual loops. The cranial 
extent of other bowel outlining should be 2 cm beyond 
the superior extent of the standard PTV or large PTV as 
appropriate.
Both the femoral heads are outlined to the bottom of 
the femoral head curvature. The femoral necks are not 
included.
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Table 3 Target volume constraints
Dose constraints Optimal Mandatory
PTV D98% ≥95% of prescribed 
dose
≥90% of prescribed 
dose
PTV D50% ±1% of prescribed 
dose
–
PTV D2% ≤105% of 
prescribed dose
≤107% of prescribed 
dose
Normal tissue D1cc – ≤110% of prescribed 
dose
PTV D98% is the dose received by 98% of planning target volume 
(PTV).
PTV D50% is the dose received by 50% of PTV.
PTV D2% is the dose received by 2% of PTV.
Normal tissue D1cc is the dose received by 1 cm
3 of normal 
tissue outside the PTV.
Table 4 Organ at risk dose constraint guide
Organ at risk
Constraint*
Dose level Optimal Mandatory
Rectum 17 Gy 50% 80%
28 Gy 20% 60%
33 Gy 15% 50%
36 Gy 5% 30%
Other bowel V25 139 cm3 208 cm3
V28 122 cm3 183 cm3
V31 105 cm3 157cm3
V33 84 cm3 126 cm3
V36 26 cm3 39 cm3
Femoral heads 28 Gy – 50%
*The constraints provided serve only as a guide with 
recommendation that the optimal constraints particularly for other 
bowel should be met for the small plan and mandatory constraints 
should be met for medium plan.
radiotherapy planning
Three- dimensional conformal radiotherapy planning is 
recommended using three or four fields; however, use of 
static 5–7- field IMRT or volumetric modulated arc radio-
therapy treatment is permitted. It is accepted that the 
preferred treatment planning method may vary between 
participating centres but should be stated at the start of 
the trial and then be used for all patients enrolled there.
For patient’s randomised to standard planning, a single 
plan is created. For those patients randomised to adaptive 
planning, a series of three plans are created using PTV 
small, PTV medium and PTV large.
Three- dimensional dose distributions are produced 
for the overall prescribed dose of 36 Gy in six fractions. 
The dose distribution is assessed for coverage of the PTV 
and normal tissues sparing using appropriate transverse 
sagittal and coronal views.
All plans are created to ensure that at least 98% of the 
PTV (PTV D98%) receives >90% (ideally >95%) of the 
prescribed dose, the median PTV dose (PTV D50%) is within 
1% of the prescription dose and the near maximum (PTV 
D2%) is <107% (ideally <105%) of the prescribed dose. 
To minimise unexpected high dose outside the PTV, it 
is required that 1 cm3 of normal tissue outside the PTV 
should be <110% of the prescribed dose.
Dose to OARs should be as low as possible. To mini-
mise dose to other bowel, it is recommended that the 
small plan for those randomised to adaptive radiotherapy 
aims to achieve the predefined optimal dose constraints, 
and the mandatory constraints for the medium plan. It 
is accepted that the rectum and bowel dose constraints 
of the large plan may not be met despite adequate opti-
misation. Assessment of other bowel dose on the large 
plan represents an overestimation of true dose to other 
bowel compared with when this plan is actually used to 
deliver treatment. This is because when the large plan is 
selected for treatment, a proportion of bowel moves out 
of the field with bladder filling. It is at the local principals’ 
investigator discretion to accept the OARs doses.
The target volume and OAR dose volume constraints 
are summarised in tables 3 and 4, respectively.
Preradiotherapy checks
To minimise risk of error at the time of plan importing, 
exporting and plan selection, it is recommended that 
each beam name and identification reflects the assigned 
plan. It is also important to ensure that the participating 
centre’s local record and verify systems cannot mix 
beams from different plans at the time exporting from 
the treatment planning system and importing for treat-
ment delivery. One way of achieving this is to create each 
plan with slightly different contributions from each field 
so that only the correct combination of beams can be 
chosen on any given day.Adding two points diagonally on 
the isocentre slice with a dose close to the 100% isodose 
would achieve this. All beams can then only be assigned 
from the same plan to each of the points as the reference 
point differs.
treatment delivery
The same patient preparation instructions used at plan-
ning CT will be implemented prior to each fraction 
delivered.
CBCT of the pelvis should be acquired prior to each 
fraction irrespective of randomisation. For those patients 
randomised to standard (control) arm, pretreatment 
CBCT should be used in accordance with guidance 
provided in the NRIG IGRT report.20 It is therefore 
expected that this CBCT will inform appropriate correc-
tions (either manual or automatic) to be applied prior to 
the delivered fraction to ensure that treatment is accu-
rately directed.
For those patients randomised to the adaptive (exper-
imental) arm, the pretreatment CBCT is acquired and 
registered to bone in accordance with the guidance 
provided in the NRIG IGRT report.20 Appropriately 
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trained radiographers or other practitioners review the 
bone- matched CBCT assessing the bladder size and 
position in relation to the three PTVs and the coverage 
they provide. The PTV contour and corresponding plan 
providing the most suitable coverage with minimal normal 
tissue irradiation is selected. The most suitable contour is 
deemed to be that which encompasses the whole bladder 
CTV as seen on CBCT with an approximate 3 mm margin 
to account for any intrafraction filling that may occur 
during treatment delivery. A second appropriately trained 
radiographer or practitioner must confirm the selected 
PTV and corresponding plan. Once agreement has been 
reached, any necessary couch correction is performed 
prior to treatment delivery with the selected plan.
If no PTV contour appears to provide suitable coverage 
of the bladder CTV, then it is advised that the patient is 
removed from the treatment couch and is asked to empty 
their bladder and, or bowel. The above steps are repeated 
with CBCT acquired just prior to treatment to reassess 
bladder. It advised that the centre contacts the RTTQA 
Group for advice if the PTV still appears to provide inad-
equate target coverage.
treatment scheduling
Treatment can be scheduled to start on any day of the 
week but each fraction should be delivered on the same 
day of the week at weekly intervals±2 days. Therefore, a 
maximum interval of 9 days between fractions is accept-
able in the event of machine breakdown or service. For 
any gaps longer than this, the participating centre is 
advised to contact the trial team.
radiotherapy protocol compliance programme
A comprehensive radiotherapy quality assurance (QA) 
programme led by the RTTQA Group has been imple-
mented for the HYBRID trial, and has been previously 
described.22 23 The QA programme aims to standardise 
contouring, planning and delivery of image guided and 
adaptive bladder radiotherapy in participating centres. 
It comprises of both pretrial and on- trial components 
including independent monitoring of appropriate treat-
ment plan selection for the adaptive planning during 
patient recruitment.
Prior to trial, entry participating centres are asked to 
complete an online facility questionnaire in order to 
gauge current local IGRT experience. A separate process 
document is used to collect task details of all aspects of a 
complete patient pathway.
The principal investigator (PI) at each participating 
centre is asked to contour two benchmark clinical cases as 
per protocol. Structured feedback is provided via RTTQA 
Group to the PI.
All participating trial centres are required to complete 
a planning benchmark case. Centres are provided with 
access to CT Digital Imaging and Communications in 
Medicine (DICOM) data and preoutlined structure set. 
They are requested to then plan this patient in their 
own treatment planning system as if randomised to the 
HYBRID adaptive arm. It is the responsibility of the local 
investigator to ensure that appropriate plan checking 
QA process is in place at their local institution. Once the 
three plans of the benchmark case have been created, 
reviewed and accepted by the local PI, the DICOM CT, 
dose cubes, RT plan and structure sets are returned in to 
the RTTQA Group via secure file transfer and structured 
feedback is provided.
It is a pretrial requirement that all participating centres 
have both an established IGRT training programme in 
place for their radiographers and be using CBCT to assess 
bladder treatment delivery. Trial- specific bladder IGRT 
competency is completed through an online training 
package, practical workshop and independent assess-
ment of plan selection.
The online training consists of three practice cases each 
with six CBCTs to work through. Step- by- step instructions 
with correct plan selections is provided. Following this, a 
credentialing assessment consisting of 12 plan selections 
is carried out. The plan selections and matched reviews 
are assessed by the RTTQA Group and structured feed-
back provided. Only those who meet minimum threshold 
of concordance of plan selection as predefined by the 
trial team will be approved for performing HYBRID plan 
selection.
As part of the on- trial QA, each participating centre 
visited by the RTTQA Group during their first adaptive 
patient’s treatment course for an on- site review of the 
local image registration processes and plan selection 
decision- making. Once the first adaptive patient has 
been recruited from each participating centre, the plans 
and plan selections for treatment delivery will be retro-
spectively reviewed remotely prior to the second patient 
starting treatment.
All planning data and treatment delivery data (CBCT, 
registration objects and treatment forms) are collected 
and reviewed by the RTTQA Group to ensure adherence 
to the HYBRID planning and delivery protocol is main-
tained. Remote retrospective plan selection review will 
take place for all adaptive radiotherapy patients during 
the trial.
statistical considerations
The primary objective is to assess whether adaptive radio-
therapy techniques when delivered at multiple centres 
can lead to a reduction in the level of acute non- GU 
toxicity experienced by patients with MIBC unsuitable for 
daily radical radiotherapy.
The sample size is based on the primary endpoint of 
acute (up to 3 months after the end of radiotherapy) 
non- GU CTCAE >grade 3 toxicity. An A’Hern exact phase 
II design was used to rule out an upper limit for each 
planning method separately. Based on results of the 
non- randomised single centre phase II feasibility study 
of adaptive predictive planning for hypofractionated 
bladder radiotherapy (APPLY study; NCT01000129),18 it 
is expected that the acute non- GU >grade 3 rate will be 
10% (p1=0.9) in patients receiving adaptive planning. The 
Protected by copyright.
 o
n
 M
ay 28, 2020 at Institute of Cancer Research The Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-037134 on 26 May 2020. Downloaded from 
8 Hafeez S, et al. BMJ Open 2020;10:e037134. doi:10.1136/bmjopen-2020-037134
Open access 
study is designed to rule out a 30% (p0=0.7) upper limit 
of >grade 3 non- GU toxicity with each planning method. 
For 80% power (β=0.2)and 5% alpha (one- sided) in each 
planning group, 28 evaluable patients are required and 
if 5 or more experience non- GU >grade 3 toxicity, then 
the acute toxicity associated with that planning technique 
will be assumed to be too high. To be evaluable for acute 
toxicity, participants must receive at least one fraction of 
radiotherapy. Incorporating a 10% non- evaluable rate 
gives a target sample size of 62 patients (31 in each plan-
ning group).
The numbers and proportions of patients with acute 
non- GU CTCAE V.4 toxicity >grade 3 within the first 3 
months of completing radiotherapy in each planning 
method will be presented together with 95% one- sided 
exact CIs (the 90% two- sided CI will also be presented).
Late toxicity will be summarised by frequencies and 
proportions at each time point by treatment group. 
Kaplan- Meier methods will be used to present time 
to event outcomes; due to small numbers, no formal 
comparison is planned.
Ethics
The trial is approved by the London- Surrey Borders 
Research Ethics Committee (13/LO/1350).
safety reporting
Data are collected at each trial visit regarding any adverse 
events according to the CTCAE V.4.0 grading system. 
The highest grade observed since the last visit should be 
reported. All serious adverse events (SAEs) are reported 
to the ICR- CTSU within 24 hours of the PI becoming 
aware of the event. SAEs should be followed up until clin-
ical recovery is complete or until the condition has stabi-
lised. Any safety concerns will be reported to the main 
research and ethics committee by ICR- CTSU as part of 
the annual progress report.
trial monitoring and oversight
The trial is supervised by a Trial Management Group 
(TMG) that includes the Chief Investigator, trials unit 
scientific lead, statistician and coordinators along with 
coinvestigators, identified collaborators including RTTQA 
Group representative, and lay/consumer representative.
Oversight is provided by an independent trials steering 
committee and an independent data monitoring 
committee (IDMC).
There are no formal early stopping rules for efficacy 
or toxicity but, as per the statistical design, if five or 
more participants report non- GU >grade 3 toxicities in 
one planning group then randomisation will cease. The 
IDMC would then review the data and advise on continu-
ation of recruitment to the other planning method.
trial status and dissemination of results
The first patient was registered in April 2014. The study 
completed recruitment in August 2016. It is expected that 
the trial will report in 2020. The results will be disseminated 
via peer- reviewed scientific journals, conference presenta-
tions and submission to regulatory authorities.
Patient and public involvement
The HYBRID trial has been reviewed and endorsed by 
patient and carer representatives from the National 
Cancer Research Institute (NCRI) Consumer Liaison 
Group and the NCRI Clinical and Translational Radio-
therapy Research Group working group.
Patient and public involvement began at the protocol 
design and development stage via national and local 
consumer oversight committee review. This included the 
NIHR Biomedical Research Centre radiotherapy studies 
consumer panel at the ICR and The Royal Marsden NHS 
Foundation Trust, and the NCRI Bladder Clinical Studies 
Group, which includes consumer representation.
Patients who had participated in the phase I study were 
asked to assess the burden of involvement required for 
participation in the HYBRID trial. This included review of 
the patient- reported outcomes questionnaires.
The trial patient information sheet and consent 
form were reviewed by the South West London Cancer 
Research Network consumer group. Their feedback was 
adopted and incorporated in to the final version of both 
documents. Copy of the ethics approved final version of 
the patient information sheet and consent is provided in 
the online supplementary file 2.
Patient representation on the TMG advises on day- 
to- day management of the trial including patient recruit-
ment, and it is expected that they will also participate in 
dissemination of results via patient groups with bladder 
cancer.
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